A conference at the European Parliament on October 1, hosted by MEP Valentina Palmisano and organized by the Longevity Policies Association and International Longevity Alliance, pressed for geroscience and preventive medicine to be treated as a distinct EU health policy field rather than a subset of pension and social care planning. Speakers from the Commission, clinical practice and research argued that biomedical advances in aging biology stall without a framework to carry them into population health. The practical test is whether the effort secures funding in FP10 and regulatory language, not whether it generates further discussion.
Key Points
- First European Parliament conference dedicated to geroscience and healthy longevity policy
- Organizers seek longevity reclassified from demography to standalone health policy
- Success depends on FP10 budget allocation and regulatory drafting, not advocacy
Longevity Analysis
The gap between validated interventions and accessible clinical practice is a distribution problem, not a scientific one, and it determines whether work on regeneration, metabolic function and immune resilience reaches anyone beyond those who can pay privately. Policy frameworks decide which preventive measures are reimbursed, which biomarkers physicians are permitted to track, and how early intervention begins relative to disease onset. Individuals retain control over what they remove, measure and practice daily, but the ceiling on that effort is set by what health systems fund and approve.
Original published by Longevity.Technology, by Eleanor Garth.